Aliases & Classifications for Endometriosis

MalaCards integrated aliases for Endometriosis:

Name: Endometriosis 12 75 37 29 55 43 44 15 63 17 72 33

Classifications:



External Ids:

Disease Ontology 12 DOID:289
KEGG 37 H01639
ICD9CM 35 617 617.9
MeSH 44 D004715
NCIt 50 C3014
SNOMED-CT 68 11871002
ICD10 33 N80 N80.9
UMLS 72 C0014175

Summaries for Endometriosis

MedlinePlus : 43 What is endometriosis? The uterus, or womb, is the place where a baby grows when a woman is pregnant. It is lined with tissue (endometrium). Endometriosis is a disease in which tissue that is similar to the lining of the uterus grows in other places in your body. These patches of tissue are called "implants," "nodules," or "lesions." They are most often found On or under the ovaries On the fallopian tubes, which carry egg cells from the ovaries to the uterus Behind the uterus On the tissues that hold the uterus in place On the bowels or bladder In rare cases, the tissue may grow on your lungs or in other parts of your body. What causes endometriosis? Researchers don't know what causes endometriosis. Who is at risk for endometriosis? Endometriosis is most commonly diagnosed in women in their 30s and 40s. But it can affect any female who menstruates. Certain factors can raise or lower your risk of getting it. You are at higher risk if You have a mother, sister, or daughter with endometriosis Your period started before age 11 Your monthly cycles are short (less than 27 days) Your menstrual cycles are heavy and last more than 7 days You have a lower risk if You have been pregnant before Your periods started late in adolescence You regularly exercise more than 4 hours a week You have a low amount of body fat What are the symptoms of endometriosis? The main symptoms of endometriosis are Pelvic pain, which affects about 75 percent of women with endometriosis. It often happens during your period. Infertility, which affects up to half of all women with endometriosis Other possible symptoms include Painful menstrual cramps, which may get worse over time Pain during or after sex Pain in the intestine or lower abdomen Pain with bowel movements or urination, usually during your period Heavy periods Spotting or bleeding between periods Digestive or gastrointestinal symptoms Fatigue or lack of energy How is endometriosis diagnosed? Surgery is the only way to know for sure that you have endometriosis. First, however, your health care provider will ask about your symptoms and medical history. You will have a pelvic exam and may have some imaging tests. The surgery to diagnose endometriosis is a laparoscopy. This is a type of surgery that uses a laparoscope, a thin tube with a camera and light. The surgeon inserts the laparoscope through a small cut in the skin. Your provider can make a diagnosis based on how the patches of endometriosis look. He or she may also do a biopsy to get a tissue sample. What are the treatments for endometriosis? There is no cure for endometriosis, but there are treatments for the symptoms. Your health care provider will work with you to decide which treatments would be best for you. Treatments for endometriosis pain include Pain relievers, including nonsteroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen and a prescription medicine specifically for endometriosis. Providers may sometimes prescribe opioids for severe pain. Hormone therapy, including birth control pills, progestin therapy, and gonadotropin-releasing hormone (GnRH) agonists. GnRH agonists cause a temporary menopause, but also help control the growth of endometriosis. Surgical treatments for severe pain, including procedures to remove the endometriosis patches or cut some nerves in the pelvis. The surgery may be a laparoscopy or major surgery. The pain may come back within a few years after surgery. If the pain is very severe, a hysterectomy may be an option. This is a surgery to remove the uterus. Sometimes providers also remove the ovaries and fallopian tubes as part of a hysterectomy. Treatments for infertility caused by endometriosis include Laparoscopy to remove the endometriosis patches In vitro fertilization NIH: National Institute of Child Health and Human Development

MalaCards based summary : Endometriosis is related to mullerian aplasia and leiomyoma, uterine, and has symptoms including pelvic pain and pain and other symptoms associated with female genital organs. An important gene associated with Endometriosis is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are MicroRNAs in cancer and miRNA targets in ECM and membrane receptors. The drugs Goserelin and Dienogest have been mentioned in the context of this disorder. Affiliated tissues include uterus, ovary and colon.

Disease Ontology : 12 A female reproductive system disease characterized by the growth of endometrial tissue outside the uterine body.

KEGG : 37
Endometriosis is defined as the growth of the endometrial glands and stroma at extra-uterine sites, which are most commonly implanted over and under visceral and peritoneal surfaces within the female pelvis but which can also be found in the connective tissue in the pelvis areas and, more rarely, in any anatomic district. It is a major cause of infertility, dysmenorrhea, dyspareunia, and chronic pelvic pain, mediated by marked pelvic inflammation. While retrograde menstruation is the most widely accepted cause, its pathogenesis and natural course are not fully understood. Endometriosis is known to be a estrogen-dependent disease, manifests during reproductive years.

PubMed Health : 63 About endometriosis: Endometriosis is one of the most common medical conditions affecting the abdomen (lower belly) in women. In endometriosis, the kind of tissue that normally lines the inside of the womb (endometrial tissue) also grows outside of it. The medical term for endometrial tissue that has grown outside of the womb is “endometrial implants.” Some women have them without knowing it. But other women experience endometriosis as a chronic disease that causes severe pain and fertility problems. It often takes years for endometriosis to be diagnosed as the cause of these problems. Until the diagnosis is made, many women try to cope with their pain somehow. They believe that the pain – even really bad pain – is a normal part of their menstrual period. There is currently no cure for endometriosis. But there are many things that can be done to relieve the symptoms. If treatment is adapted to suit women’s personal circumstances and the severity of their endometriosis, many can cope quite well with the disease. Like with other chronic conditions, it's important to get to know your own body and how it reacts, in order to find ways to manage the symptoms. Getting hold of good information and consulting experienced, supportive doctors can help.

Wikipedia : 75 Endometriosis is a condition in which cells similar to those in the endometrium, the layer of tissue... more...

Related Diseases for Endometriosis

Diseases in the Endometriosis family:

Endometriosis 1

Diseases related to Endometriosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 678)
# Related Disease Score Top Affiliating Genes
1 mullerian aplasia 31.1 WNT4 H19
2 leiomyoma, uterine 30.5 MIR29C MIR196B MIR150
3 coronary heart disease 1 30.3 MIR145 MIR126 H19 CDKN2B-AS1
4 cervical cancer 29.9 MIR196B MIR143 H19 CDKN2B-AS1
5 melanoma 29.6 MIR200B MIR200A MIR141 MIR100 H19 CDKN2B-AS1
6 leukemia, acute lymphoblastic 29.5 MIR424 MIR196B MIR125A
7 psoriasis 29.4 MIR20A MIR200A MIR141 MIR100
8 bladder cancer 28.7 MIR99A MIR29C MIR145 MIR143 MIR100 H19
9 colorectal cancer 28.5 MIR20A MIR145 MIR143 MIR141 MIR126 MIR125A
10 breast cancer 28.1 MIR29C MIR20A MIR200B MIR200A MIR145 MIR143
11 kidney cancer 28.0 MIR424 MIR29C MIR20A MIR200B MIR150 MIR141
12 pancreatic cancer 27.7 MIR99A MIR424 MIR20A MIR143 MIR125A MIR100
13 ovarian cancer 27.2 MIR99A MIR424 MIR29C MIR200B MIR200A MIR150
14 prostate cancer 26.8 MIR99A MIR20A MIR200B MIR145 MIR143 MIR141
15 endometriosis of ovary 12.8
16 extrapelvic endometriosis 12.5
17 fallopian tube endometriosis 12.5
18 adenomyosis 12.5
19 endometriosis of pelvic peritoneum 12.4
20 cervix endometriosis 12.4
21 endometriosis 1 12.4
22 endometriosis of intestine 12.3
23 endometriosis of rectovaginal septum and vagina 12.3
24 endometriosis in scar of skin 12.3
25 catamenial pneumothorax 11.8
26 adenosarcoma 11.7
27 chronic pain 11.6
28 uterine anomalies 11.5
29 benign multicystic peritoneal mesothelioma 11.2
30 infertility 11.2
31 ovarian cyst 10.8
32 pneumothorax 10.7
33 adenocarcinoma 10.7
34 hydronephrosis 10.7
35 constipation 10.7
36 leiomyoma 10.6
37 intestinal obstruction 10.6
38 enhanced s-cone syndrome 10.6
39 endometrial cancer 10.6
40 ureteral obstruction 10.6
41 appendicitis 10.6
42 progesterone resistance 10.5
43 amenorrhea 10.5
44 myoma 10.5
45 ovarian epithelial cancer 10.5
46 intussusception 10.5
47 ovarian clear cell carcinoma 10.5
48 clear cell adenocarcinoma 10.5
49 autoimmune disease 10.5
50 endometrial stromal sarcoma 10.5

Comorbidity relations with Endometriosis via Phenotypic Disease Network (PDN):


Myofibroma

Graphical network of the top 20 diseases related to Endometriosis:



Diseases related to Endometriosis

Symptoms & Phenotypes for Endometriosis

UMLS symptoms related to Endometriosis:


pelvic pain, pain and other symptoms associated with female genital organs

Drugs & Therapeutics for Endometriosis

PubMed Health treatment related to Endometriosis: 63

There is currently no “cure” for endometriosis – in other words, there are no treatments that can fight what is causing it. But various treatments can help relieve the symptoms, temporarily or permanently. The medication options include painkillers, hormonal contraception and stronger hormone therapy. Painkillers only relieve the symptoms, whereas hormone-based treatments slow down the growth of endometrial implants. Surgery is also an option. The aim of surgery for endometriosis is usually to remove as many endometrial implants as possible. Sometimes surgery is even necessary – for instance, if endometriosis is affecting bowel or bladder function.

Drugs for Endometriosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 337)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Goserelin Approved Phase 4 65807-02-5, 1233494-97-7 47725 5311128
2
Dienogest Approved Phase 4 65928-58-7
3
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
4
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
5
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
6
Desogestrel Approved Phase 4 54024-22-5 40973
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
Drospirenone Approved Phase 4 67392-87-4 68873
9
Resveratrol Approved, Experimental, Investigational Phase 4 501-36-0 445154
10
Sage Approved Phase 4
11
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
12
Loperamide Approved Phase 4 53179-11-6 3955
13
Opium Approved, Illicit Phase 4 8008-60-4
14
Glycerol Approved, Investigational Phase 4 56-81-5 753
15
Belladonna Approved, Experimental Phase 4
16
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887 16129715
17
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
18
Misoprostol Approved Phase 4 59122-46-2 5282381
19
tannic acid Approved Phase 4 1401-55-4
20
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
21
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
22
Polyestradiol phosphate Approved Phase 4 28014-46-2
23
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
24
Norethindrone Approved Phase 4 68-22-4 6230
25
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
26
Tibolone Approved, Investigational Phase 4 5630-53-5
27
Calcium carbonate Approved, Investigational Phase 4 471-34-1
28
Buserelin Approved, Investigational Phase 4 57982-77-1
29
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
30
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
31
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
32
Norgestrel Approved Phase 4 6533-00-2 13109
33
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
34
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
35
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
36
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
37
Norepinephrine Approved Phase 4 51-41-2 439260
38
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
39
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
40
St. John's Wort Approved, Investigational, Nutraceutical Phase 4 84082-80-4
41
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
42 Gallopamil Investigational Phase 4 16662-47-8
43
Nandrolone Experimental, Investigational Phase 4 434-22-0 9904
44
Enclomiphene Investigational Phase 4 15690-57-0
45 Deslorelin Investigational, Vet_approved Phase 4 57773-65-6
46 Protective Agents Phase 4
47 Androgens Phase 4
48 Anabolic Agents Phase 4
49 Narcotics Phase 4
50 Analgesics, Opioid Phase 4

Interventional clinical trials:

(show top 50) (show all 521)
# Name Status NCT ID Phase Drugs
1 Phase IV Pilot Study of Ulipristal Acetate for Treatment of Endometriosis-related Pelvic Pain Unknown status NCT02213081 Phase 4 Ulipristal
2 A Randomized Study Comparing Goserelin or Expectant Management Following Laparoscopic Surgery for Advanced Endometriosis Unknown status NCT00654524 Phase 4 gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin
3 Randomised, Controlled Clinical Study With Patients With Endometriosis and the Desire to Have Children - Comparison Between Peritoneal Ablation by Excision Only and Excision With the Use of an Adhesionbarrier Unknown status NCT02165917 Phase 4
4 A Prospective, Randomized Controlled Trial Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery Unknown status NCT02385448 Phase 4 Dienogest;Microgynon
5 Continuous Versus Cyclic Use of Oral Contraceptives Following Surgery for Symptomatic Endometriosis Unknown status NCT02237131 Phase 4 Oral contraceptives cyclic;Oral contraceptives continuous
6 Continuous Versus Cyclic Postoperative Use of Low-Dose Combined Oral Contraceptive Belara® for the Treatment of Endometriosis-Related Chronic Pelvic Pain: a Randomized Controlled Trial. Unknown status NCT00844012 Phase 4 Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy);Cyclic OC (clormadinone acetate plus ethinil-estradiol)
7 A Randomized, Double-blind, Placebo-controlled Post-marketing Study to Assess the Treatment Effect of Sanjie Analgesic Capsule in Treating Endometriosis - Associated Pain Unknown status NCT02031523 Phase 4 Sanjie analgesic capsule;placebo
8 Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 11 With and Without Suppression by Dienogest Unknown status NCT02575248 Phase 4 Dienogest 2mg;Clomiphene citrate 5 mg
9 Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
10 Electrosurgical Unipolar Vessel Sealing Versus Purohit Technique in Vaginal Hysterectomy . ( A Pilot Randomized Clinical Trial) Unknown status NCT03228654 Phase 4
11 Treatment of Patients With Endometriosis Recurrence With Aromatase Inhibitor (Anastrazole) Plus GnRH-agonist (Luprolide). Completed NCT01769781 Phase 4 anastrazole;GnRH analog alone
12 Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis Completed NCT00286351 Phase 4 Combined treatment with Arimidex and Zoladex before IVF
13 IVF Outcome in Patients With Peritoneal Endometriosis. The Impact of a Hormonal Treatment of the Endometriosis Prior to the IVF on the Pregnancy Rates. Completed NCT01682642 Phase 4 Zoladex
14 Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions. Completed NCT00625950 Phase 4
15 Phase 4 Randomized Controlled Trial of Dynamized Estrogen in Individualized Homeopathic Treatment of Chronic Pelvic Pain of Endometriosis Completed NCT02427386 Phase 4 dynamized estrogen;placebo
16 A Comparative Study, Randomized, Blinded, About the Effect of Pre-treatment With GnRH Analogues Versus Placebo in Infertile Patients With Endometriosis Undergoing in Vitro Fertilization Treatment Completed NCT01581359 Phase 4 Triptorelin acetate
17 Treatment With Danazol Before Controlled Ovarian Hyperstimulation in Women With Endometriosis Undergoing IVF Completed NCT01779232 Phase 4 Danazol;placebo
18 Postoperative Intramuscular Depot Medroxyprogesterone Acetate Versus Continuous Oral Contraceptive for Pelvic Pain Associated With Endometriosis : Randomized Comparative Trial. Completed NCT01056042 Phase 4 intramuscular depot medroxyprogesterone acetate;ethinyl estradiol 30 micrograms, gestodene 75 micrograms
19 Effects of the Levonorgestrel-releasing Intrauterine System Compared With the Leuprolide Acetate in Patients With Endometriosis: a Randomized Trial Completed NCT02158845 Phase 4 LNG-IUS: levonorgestrel intrauterine system;GnRHa: leuprolide
20 Randomized Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Pelvic Pain Control in Women With Endometriosis Completed NCT02480647 Phase 4 Levonorgestrel;Etonogestrel
21 Do Endometrial Implantation Markers Predict in Vitro Fertilization-Embryo Transfer Cycle Outcomes in Endometriosis Patients Pretreated With Leuprolide Acetate in Depot Suspension? Completed NCT00621179 Phase 4 Leuprolide acetate in depot suspension;Leuprolide acetate;leuprolide acetate
22 Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients Completed NCT02534688 Phase 4 LNG-IUS;DMPA
23 The Use of Resveratrol for Pain in Endometriosis - A Clinical Trial Completed NCT02475564 Phase 4 Placebo;Resveratrol
24 SAGE: Supplementation in Adolescent Girls With Endometriosis Completed NCT02387931 Phase 4
25 A Prospective Single Centre, Single Arm, Open Label Study of the Long Term Use of a LHRA Agonist (Decapeptyl SR, 11.25mg) in Combination With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women Completed NCT00735852 Phase 4 Decapeptyl SR 11.25mg
26 Understanding Experimentally Induced Hot Flushes and Their Impact on Sleep and Mood Completed NCT00455689 Phase 4 Leuprolide acetate
27 Impact of Experimentally Induced Hot Flashes on Sleep and Mood Disturbance Completed NCT01116401 Phase 4 leuprolide
28 Intra-uterine Injection of Human Chorionic Gonadotrophin Before Embryo Transfer in ICSI Completed NCT01030393 Phase 4 human chorionic gonadotrophin
29 Effects of St. John's Wort on Levonorgestrel Completed NCT00131885 Phase 4 Levonorgestrel
30 Barbed Suture vs Smooth Suture for Vaginal Cuff Closure, a Randomized Trial Completed NCT01262573 Phase 4
31 Which do You Think is the Best Treatment Choice in Primary Dysmenorrhea? Completed NCT03124524 Phase 4 estradiol valerate/dienogest;ethinylestradiol and drospirenone
32 The Use of Mild Stimulation Protocol in Poor Responders : a Randomized Trial Completed NCT01213147 Phase 4 clomiphene citrate;buserelin
33 Belladonna and Opium Rectal Suppository Effect on Postoperative Pain and Nausea Following Total Laparoscopic and Robotic-Assisted Hysterectomy Completed NCT03657407 Phase 4 Belladonna Opium;Glycerin Suppository
34 Estimation of Vascularization After Treatment of Deep Rectovaginal Endometriosis Node by Rectal Shaving, Using Indocyanine Green Injection. Feasibility Study Recruiting NCT03080558 Phase 4 Indocyanine green
35 Effects of Dienogest and Dienogest Plus Estradiol Valerate on Ovarian Reserve and Endometrioma Size Recruiting NCT03789123 Phase 4 Estradiol valerate/dienogest
36 Deciphering the Hormonal and Nociceptive Mechanisms Underlying Bladder Pain Recruiting NCT02214550 Phase 4 microgestin 1/20
37 A Controlled Trial on Uterine Fibroids Treatment Comparing Aromatase Inhibitor Plus GnRH Analogue Versus Ulipristal Acetate Recruiting NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
38 Coasting Versus Gonadotrophin-Releasing Hormone Antagonist Administration in Patients at High Risk of Ovarian Hyperstimulation Syndrome and Its Impact on the Embryos Quality and the Outcome of ICSI Recruiting NCT03996434 Phase 4 Gonadotropin;Antagonist
39 Efficacy of Vaginal Misoprostol For Pain Relief During Office Hysteroscopy and Endometrial Biopsy; A Double Blind Randomized Controlled Trial Recruiting NCT03547778 Phase 4 Misoprostol 50 mcg pesssary;Placebos
40 Effect of Deep Versus Moderate Neuromuscular Blockade on Peak Airway Pressures During Elective Laparoscopic Surgery Enrolling by invitation NCT02812186 Phase 4 Rocuronium
41 Psychological Impact of Amenorrhea in Women With Endometriosis: Perspective Randomized Study Not yet recruiting NCT02393482 Phase 4 Estroprogestinic therapy (Etinil-estradiol/levonorgestre);Gonadotropin-releasing hormone agonist (Leuprorelin acetate);Add back therapy 1 (tibolone);Add back therapy 2 (calcium carbonate/colecalciferol)
42 Can Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist Withstand When Administered at Different Points in the Menstrual Cycle? Not yet recruiting NCT04060992 Phase 4 Elagolix 200 MG Oral Tablet [Orilissa]
43 Trans-vaginal Aspiration With or Without Injection of Surgicel for Treatment of Small Ovarian Endometrioma Before ICSI Cycles. A Randomized Controlled Trial Not yet recruiting NCT03784404 Phase 4 Intracytoplasmic sperm injection
44 Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. Not yet recruiting NCT03946722 Phase 4 GnRH analogue downregulation
45 The Effectiveness and Safety of the Early Follicular Phase Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation: a Randomized, Paralleled, Controlled, Multicenter Trial Not yet recruiting NCT03809221 Phase 4 Triptorelin acetate
46 Comparison of Embryo Transfer With and Without PGS for the Indication of Advanced Reproductive Age (37-42) in Patients Undergoing ART Suspended NCT00646893 Phase 4
47 A Single Centre Open-label Randomised Controlled Trial of Long Term Pituitary Down-regulation Before in Vitro Fertilisation for Women With Endometriosis: a Pilot Study Terminated NCT01757249 Phase 4 Combined Oral Contraceptive Pill (Microgynon 30)
48 Peritoneal Cavity Conditioning During Laparoscopic Surgery Decreases Postoperative Pain, Inflammatory Reaction and Postoperative Adhesions Terminated NCT01344486 Phase 4
49 Evaluating Duloxetine's Analgesic Effectiveness in Chronic Pelvic Pain Terminated NCT01451606 Phase 4 Duloxetine;Placebo
50 Initiation of Medical Menopause With Depot Leuprolide Acetate vs Depot Leuprolide Acetate Plus Medroxyprogesterone Acetate: A Pilot Randomized Terminated NCT01776203 Phase 4 Medroxyprogesterone 17-Acetate

Search NIH Clinical Center for Endometriosis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


17-alpha-Hydroxyprogesterone
Buserelin
Danazol
Danazol
Desogestrel
Drospirenone
Ethynodiol Diacetate
Goserelin
Goserelin Acetate
hydroxyprogesterone caproate (USP)
Leuprolide
Leuprolide
Leuprolide Acetate
Levonorgestrel
Medroxyprogesterone acetate
Mestranol
Nafarelin
Nafarelin
Nafarelin Acetate
Norethindrone
norethindrone acetate
Norethisterone
Norgestrel

Cochrane evidence based reviews: endometriosis

Genetic Tests for Endometriosis

Genetic tests related to Endometriosis:

# Genetic test Affiliating Genes
1 Endometriosis 29

Anatomical Context for Endometriosis

MalaCards organs/tissues related to Endometriosis:

41
Uterus, Ovary, Colon, Endothelial, Bone, Appendix, Testes

Publications for Endometriosis

Articles related to Endometriosis:

(show top 50) (show all 21598)
# Title Authors PMID Year
1
Combination of noninvasive methods in diagnosis of infertile women with minimal or mild endometriosis, a retrospective study in China. 38 17
31374059 2019
2
Comparative efficacy and safety of traditional Chinese patent medicine for endometriosis: A Bayesian network meta-analysis protocol. 38 17
31335707 2019
3
Endometriosis in pregnancy - diagnostics and management. 38 17
31213060 2019
4
MicroRNA-regulated pathways associated with endometriosis. 38 88
19074548 2009
5
Endometriotic epithelial cells induce MMPs expression in endometrial stromal cells via an NFkappaB-dependent pathway. 9 38
19903119 2010
6
Interleukin-4 induces expression of eotaxin in endometriotic stromal cells. 9 38
19338989 2010
7
Letrozole and norethisterone acetate in colorectal endometriosis. 9 38
20227163 2010
8
Matrix metalloproteinase messenger RNA expression in human endometriosis grafts cultured on a chicken chorioallantoic membrane. 9 38
19345347 2010
9
Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis. 9 38
19324337 2010
10
FSH receptor, KL1/2, P450, and PAPP genes in granulosa-lutein cells from in vitro fertilization patients show a different expression pattern depending on the infertility diagnosis. 9 38
19342032 2010
11
The roles of thioredoxin and thioredoxin-binding protein-2 in endometriosis. 9 38
20172870 2010
12
[Treatment of endometriosis by aromatase inhibitors: efficacy and side effects]. 9 38
20430665 2010
13
Steroidogenic factor-1 expression in ovarian endometriosis. 9 38
19875956 2010
14
[Aromatase and endometriosis: myth or reality]. 9 38
20430669 2010
15
[Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in human and nude mouse ectopic endometrium and the effect of estrogen and progestin on their expression]. 9 38
20423842 2010
16
17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappaB-dependent pathway. 9 38
19932734 2010
17
Estrogen and progesterone receptors in smooth muscle component of deep infiltrating endometriosis. 9 38
19217090 2010
18
Effect of human seminal fluid on the growth of endometrial cells of women with endometriosis. 9 38
20092935 2010
19
Expression of macrophage migration inhibitory factor in human endometriosis: relation to disease stage, menstrual cycle and infertility. 9 38
20492386 2010
20
Proteomic analysis of endometrium from fertile and infertile patients suggests a role for apolipoprotein A-I in embryo implantation failure and endometriosis. 9 38
20008415 2010
21
Immunohistochemical detection of steroid receptor cofactors in ovarian endometriosis: involvement of down-regulated SRC-1 expression in the limited growth activity of the endometriotic epithelium. 9 38
20155281 2010
22
Interleukin-6 and other soluble factors in peritoneal fluid and endometriomas and their relation to pain and aromatase expression. 9 38
20074813 2010
23
Analysis of matrix metalloproteinase-7 expression in eutopic and ectopic endometrium samples from patients with different forms of endometriosis. 9 38
20007614 2010
24
Non-invasive diagnosis of endometriosis based on a combined analysis of six plasma biomarkers. 9 38
20007161 2010
25
Expression of eicosanoid biosynthetic and catabolic enzymes in peritoneal endometriosis. 9 38
20023295 2010
26
Regulation of monocyte chemotactic protein-1 expression in human endometrial endothelial cells by sex steroids: a potential mechanism for leukocyte recruitment in endometriosis. 9 38
19933497 2010
27
Effect of vascular endothelial growth factor and interleukin-1beta on apoptosis in endometrial cell cultures from patients with endometriosis and controls. 9 38
20137818 2010
28
Influence of peritoneal fluid on the expression of angiogenic and proteolytic factors in cultures of endometrial cells from women with endometriosis. 9 38
19945964 2010
29
17Beta-hydroxysteroid dehydrogenase-2 deficiency and progesterone resistance in endometriosis. 9 38
20108182 2010
30
Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. 9 38
20104427 2010
31
Molecular mechanisms of treatment resistance in endometriosis: the role of progesterone-hox gene interactions. 9 38
20104430 2010
32
Lipopolysaccharide promoted proliferation and invasion of endometriotic stromal cells via induction of cyclooxygenase-2 expression. 9 38
19647233 2010
33
Cadherin expression in gastrointestinal tract endometriosis: possible role in deep tissue invasion and development of malignancy. 9 38
19898423 2010
34
Haptoglobin expression in endometrioid adenocarcinoma of the uterus. 9 38
19801537 2010
35
Expression of cyclooxygenase-2 in eutopic endometrium and ovarian endometriotic tissue in women with severe endometriosis. 9 38
20068324 2010
36
Association of interleukin 1beta gene (+3953) polymorphism and severity of endometriosis in Turkish women. 9 38
19757173 2010
37
Peritoneal vascular density assessment using narrow-band imaging and vascular analysis software, and cytokine analysis in women with and without endometriosis. 9 38
19892605 2010
38
Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases. 9 38
20085636 2010
39
Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. 9 38
19726448 2009
40
HOXA-10 expression in the mid-secretory endometrium of infertile patients with either endometriosis, uterine fibromas or unexplained infertility. 9 38
19736237 2009
41
Cyclooxygenase-2 expression, Ki-67 labeling index, and perifocal neovascularization in endometriotic lesions. 9 38
19917472 2009
42
Electrodermal measures of Jing-Well points and their clinical relevance in endometriosis-related chronic pelvic pain. 9 38
19958132 2009
43
Effect of Yikun Neiyi Wan on the expression of aromatase P450, COX-2, and ER related receptor in endometrial cells in vitro from patients with endometriosis. 9 38
20112494 2009
44
Elevated ghrelin levels in the peritoneal fluid of patients with endometriosis: associations with vascular endothelial growth factor (VEGF) and inflammatory cytokines. 9 38
18976754 2009
45
Fenofibrate causes regression of endometriotic implants: a rat model. 9 38
19580963 2009
46
Recent patent trends in the field of progesterone receptor agonists and modulators. 9 38
19785507 2009
47
Hepatocyte nuclear factor-1beta(HNF-1beta) in human urogenital organs: its expression and role in embryogenesis and tumorigenesis. 9 38
19760597 2009
48
Correlation between symptoms of pain and peritoneal fluid inflammatory cytokine concentrations in endometriosis. 9 38
19903048 2009
49
CYP17 and CYP19 gene polymorphisms in women affected with endometriosis. 9 38
18930188 2009
50
Frequency of endometriotic lesions in peritoneum samples from asymptomatic fertile women and correlation with CA125 values. 9 38
20512287 2009

Variations for Endometriosis

Expression for Endometriosis

LifeMap Discovery
Genes differentially expressed in tissues of Endometriosis patients vs. healthy controls: 35 (show top 50) (show all 83)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 PTGIS prostaglandin I2 (prostacyclin) synthase Uterus + 5.41 0.000
2 MYH11 myosin, heavy chain 11, smooth muscle Uterus + 4.87 0.001
3 ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide Uterus + 4.81 0.000
4 CNN1 calponin 1, basic, smooth muscle Uterus + 4.71 0.000
5 TAGLN transgelin Uterus + 4.63 0.000
6 PAEP progestagen-associated endometrial protein Uterus + 4.63 0.013
7 PRELP proline/arginine-rich end leucine-rich repeat protein Uterus + 4.59 0.000
8 C7 complement component 7 Uterus + 4.54 0.003
9 ACTG2 actin, gamma 2, smooth muscle, enteric Uterus + 4.48 0.003
10 TCF21 transcription factor 21 Uterus + 4.45 0.000
11 HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) Uterus - 4.42 0.001
12 WISP2 WNT1 inducible signaling pathway protein 2 Uterus + 4.11 0.001
13 AQP1 aquaporin 1 (Colton blood group) Uterus + 4.10 0.000
14 EHF ets homologous factor Uterus - 4.10 0.000
15 FOS FBJ murine osteosarcoma viral oncogene homolog Uterus + 4.09 0.000
16 FOSB FBJ murine osteosarcoma viral oncogene homolog B Uterus + 4.07 0.000
17 SLC3A1 solute carrier family 3 (amino acid transporter heavy chain), member 1 Uterus - 4.05 0.010
18 LMNB1 lamin B1 Uterus - 4.05 0.000
19 SLC26A4 solute carrier family 26 (anion exchanger), member 4 Uterus - 3.99 0.000
20 DPT dermatopontin Uterus + 3.98 0.000
21 DES desmin Uterus + 3.97 0.001
22 KCNMB1 potassium channel subfamily M regulatory beta subunit 1 Uterus + 3.96 0.001
23 GATA6 GATA binding protein 6 Uterus + 3.89 0.004
24 FZD7 frizzled class receptor 7 Uterus + 3.89 0.000
25 LEFTY2 left-right determination factor 2 Uterus + 3.88 0.001
26 SLC26A4 solute carrier family 26 (anion exchanger), member 4 Uterus - 3.87 0.001
27 HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) Uterus - 3.86 0.001
28 ACKR1 atypical chemokine receptor 1 (Duffy blood group) Uterus + 3.84 0.001
29 EFHC2 EF-hand domain (C-terminal) containing 2 Uterus - 3.75 0.000
30 PDLIM3 PDZ and LIM domain 3 Uterus + 3.72 0.001
31 GPC3 glypican 3 Uterus + 3.71 0.003
32 IL20RA interleukin 20 receptor, alpha Uterus - 3.70 0.000
33 MYL9 myosin, light chain 9, regulatory Uterus + 3.70 0.001
34 VNN1 vanin 1 Uterus - 3.69 0.008
35 CTSZ cathepsin Z Uterus - 3.68 0.000
36 EHF ets homologous factor Uterus - 3.67 0.000
37 LMNB1 lamin B1 Uterus - 3.61 0.000
38 CLU clusterin Uterus + 3.58 0.002
39 ACTA2 actin, alpha 2, smooth muscle, aorta Uterus + 3.57 0.000
40 TCEAL2 transcription elongation factor A (SII)-like 2 Uterus + 3.53 0.001
41 LMOD1 leiomodin 1 (smooth muscle) Uterus + 3.52 0.003
42 LMO3 LIM domain only 3 (rhombotin-like 2) Uterus + 3.51 0.002
43 TPD52 tumor protein D52 Uterus - 3.50 0.000
44 SYNPO synaptopodin Uterus + 3.48 0.001
45 KLF2 Kruppel-like factor 2 Uterus + 3.44 0.000
46 AOC3 amine oxidase, copper containing 3 Uterus + 3.44 0.003
47 KCNK3 potassium channel, two pore domain subfamily K, member 3 Uterus + 3.44 0.007
48 ZBBX zinc finger, B-box domain containing Uterus - 3.43 0.001
49 FMO1 flavin containing monooxygenase 1 Uterus + 3.43 0.000
50 ZBBX zinc finger, B-box domain containing Uterus - 3.42 0.002
Search GEO for disease gene expression data for Endometriosis.

Pathways for Endometriosis

Pathways related to Endometriosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.89 MIR99A MIR29C MIR20A MIR200B MIR200A MIR150
2 10.77 MIR200B MIR200A MIR141
3 10.11 MIR150 MIR126

GO Terms for Endometriosis

Cellular components related to Endometriosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.4 WNT4 MIR99A MIR424 MIR29C MIR20A MIR150

Biological processes related to Endometriosis according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of angiogenesis GO:0045766 9.75 MIR20A MIR143 MIR126
2 negative regulation of inflammatory response GO:0050728 9.7 MIR20A MIR141 MIR126
3 negative regulation of protein kinase B signaling GO:0051898 9.67 MIR29C MIR20A MIR145
4 positive regulation of blood vessel endothelial cell migration GO:0043536 9.65 MIR200A MIR143 MIR126
5 negative regulation of gene expression GO:0010629 9.63 WNT4 MIR29C MIR20A MIR200B MIR125A CDKN2B-AS1
6 negative regulation of blood vessel endothelial cell migration GO:0043537 9.61 MIR424 MIR200B
7 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.61 MIR150 MIR126
8 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.61 MIR424 MIR29C MIR20A
9 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.6 MIR20A MIR145
10 negative regulation of smooth muscle cell proliferation GO:0048662 9.59 MIR145 MIR143
11 positive regulation of sprouting angiogenesis GO:1903672 9.58 MIR126 MIR125A
12 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.57 MIR424 MIR29C
13 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.56 MIR20A MIR143
14 negative regulation of fibroblast growth factor receptor signaling pathway GO:0040037 9.55 WNT4 MIR424
15 regulation of smooth muscle contraction GO:0006940 9.54 MIR145 MIR143
16 gene silencing by miRNA GO:0035195 9.53 MIR99A MIR424 MIR29C MIR20A MIR200B MIR200A
17 angiotensin-activated signaling pathway GO:0038166 9.51 MIR145 MIR143
18 negative regulation of vascular endothelial cell proliferation GO:1905563 9.5 MIR424 MIR29C MIR126
19 aorta smooth muscle tissue morphogenesis GO:0060414 9.46 MIR145 MIR143
20 negative regulation of angiogenesis GO:0016525 9.43 MIR424 MIR29C MIR200B MIR145 MIR143 MIR125A
21 regulation of phenotypic switching GO:1900239 9.4 MIR145 MIR143
22 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.37 MIR20A MIR143
23 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.26 MIR145 MIR143

Molecular functions related to Endometriosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.36 MIR424 MIR29C MIR20A MIR200B MIR200A MIR150
2 RNA polymerase II complex binding GO:0000993 9.26 MIR20A MIR145 MIR126 MIR125A

Sources for Endometriosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....